Jaguar Health, Inc. (JAGX)
| Market Cap | 2.39M -69.8% |
| Revenue (ttm) | 27.82M +135.5% |
| Net Income | -52.42M |
| EPS | -2,338.09 |
| Shares Out | 520.14K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 438,852 |
| Open | 3.940 |
| Previous Close | 4.180 |
| Day's Range | 3.940 - 4.650 |
| 52-Week Range | 2.350 - 1,260.001 |
| Beta | -0.11 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 16, 2026 |
About JAGX
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS... [Read more]
Financial Performance
In 2025, Jaguar Health's revenue was $11.51 million, a decrease of -1.52% compared to the previous year's $11.69 million. Losses were -$53.58 million, 39.2% more than in 2024.
Financial StatementsNews
Jaguar Health sets ex-dividend date for Series R preferred stock dividend
Jaguar Health (JAGX) provided an update in connection with the company’s previously announced special stock dividend, which is payable on October 15 to holders of Jaguar common stock and certain…
Jaguar Health Provides Update Regarding Special Stock Dividend
Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternatives Jaguar's rare disease intestinal failure development program for micro...
Jaguar Health’s Napo provides recap of preliminary results on crofelemer powder
Jaguar Health (JAGX) family company Napo Pharmaceuticals provided a recap of the positive preliminary results presented on October 13, 2026 at the American College of Gastroenterology Annual Scientifi...
Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for SBS-IF and microvillus inclusion disease (MVID) for crofelemer powder for oral solution, t...
Reminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock Dividend
Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternatives Jaguar's rare disease intestinal failure development program for micro...
Jaguar Health Proxy statement: Proxy filing
Jaguar Health filed a proxy statement on October 8, 2026, providing details for shareholder voting and corporate governance matters.
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and short bowel syndrome (SBS) for crofelemer powder ...
Jaguar Health announces special stock dividend
Jaguar Health (JAGX) on Friday night announced that its board of directors has declared a special stock dividend to holders of Jaguar common stock and certain outstanding warrants as of…
Jaguar Health Announces a Special Stock Dividend
Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternatives SAN FRANCISCO, CA / ACCESS Newswire / October 2, 2026 / Jaguar Health,...
Jaguar Health Proxy statement: Proxy filing
Jaguar Health filed a proxy statement on September 29, 2026, providing details for shareholder voting and corporate governance matters.
Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS-IF for crofelemer powder for oral solution, t...
Jaguar Health receives fee waivers from FDA
Jaguar Health’s (JAGX) Napo Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Napo’s request for a waiver of the fee associated with the Prescription Drug User Fee…
Jaguar Health Receives Fee Waivers from FDA
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS for crofelemer powder for oral solution, targ...
Jaguar Health Proxy statement: Proxy filing
Jaguar Health filed a proxy statement on September 18, 2026, providing details for shareholder voting and corporate governance matters.
Jaguar Health announces 1-for-15 reverse stock split
Jaguar Health (JAGX) announced that the Company will effect a reverse stock split of its issued and outstanding voting common stock, at an exchange ratio of 1-for-15, on Thursday, September…
Jaguar Health, Inc. Announces Reverse Stock Split
Reverse split approved at April 2026 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on September 17, 2026 SAN FRANCISCO, CA / ACCESS News...
Jaguar Health announces all pediatric MVID patients entered extension phase
Jaguar Health (JAGX), family company Napo Pharmaceuticals, announced that all randomized pediatric MVID patients in Napo’s crossover clinical trial have entered the single-blind extension phase to rec...
All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Continuation of treatment with blinded doses of crofelemer in the extension phase of the trial will support company's plans to file an NDA in mid-2027 for MVID, an ultrarare pediatric disease SAN FRAN...
Jaguar Health announces Neonorm Dog availability on Amazon
Jaguar Health (JAGX) announced that Neonorm Dog is now available on Amazon. A new extension of Jaguar’s Neonorm franchise for companion and production animals, Neonorm Dog is designed to provide…
Jaguar Health reports additional infant patient to receive crofelemer for IF
Jaguar Health (JAGX) announced that Jaguar family company Napo Pharmaceuticals is providing the company’s novel crofelemer powder for oral solution for treatment of intestinal failure in an infant pat...
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)
Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for pediatric and adult rare IF diseases, including microv...
Jaguar Health initiated commercial launch of Neonorm Dog
Jaguar Health (JAGX) announced the initiation of the commercial launch of Neonorm Dog, a new extension of Jaguar’s Neonorm franchise for companion and production animals. “Neonorm Dog is designed to…
Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
Neonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI ...
Jaguar Health Transcript: Investor update
Secured $18 million upfront from a Mytesi out-license, enabling a strategic focus on rare GI diseases. Crofelemer showed up to 48% reduction in parenteral support for MVID, with NDA filing targeted for mid-2027. The intestinal failure market opportunity is estimated at $8 billion.
Jaguar Health Reports Second Quarter 2026 Financials
Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure (IF) diseases; as announced , presentation at ESPGHAN 2026 described additional gro...